abstract |
The present invention relates to RNAi agents, e.g. , double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-Ll) gene, and methods of using such RNAi agents to inhibit expression of a PD-Ll gene and methods of treating subjects having a PD-Ll -associated disorder. |